OMNY, Scipher Medicine partner for autoimmune disease treatment

OMNY Health, a company that helps hospitals monetize operational data, announced a partnership with Scipher Medicine to promote precision medicine efforts for immunology. The aim of the collaboration is to integrate transcriptomic data from Scipher Medicine with OMNY Health's EHR network that extends to more than 80 million patients.  OMNY Health’s network is composed of data from almost 250,000 patients with rheumatoid arthritis that covers key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI and DAS28, which allows for the comprehensive tracking of patient outcomes and disease progression. Additionally, OMNY Health's partners in the life sciences will now have the ability to gain access to valuable clinico-transcriptomic datasets of Scipher Medicine’s PrismRA-tested patients.  The partnership comes in the wake of the 2024 launch of OMNY Health's GLP-1 database that includes more than 600,000 datasets, which enhances clinical research on GLP-1 medications, particularly for pediatrics and social determinants of health. "At OMNY Health, we are steadfast in our belief that highly targeted therapies and treatments for disease are the key to improving healthcare outcomes,” Dr. Mitesh Rao, founder and CEO of OMNY Health," said in a statement.  "Nearly 50 million Americans suffer from autoimmune diseases, and their patient experiences hold valuable insights that, if extracted, could help drive advancements in precision medicine." Dr. Reginald Seeto, president and CEO of Scipher Medicine, acknowledged the significant role clinico-transcriptomic data plays in treatment decisions and bringing precision medicine to patients. "Patients deserve clarity and personalized evidence-based answers when navigating individual treatment options. By partnering with OMNY Health, we will enable clinicians and researchers to make data-driven decisions that ultimately reduce the risk to patients," Seeto said in a statement. THE LARGER TREND Earlier this month, when asked to forecast AI's place in healthcare in 2025, Dr. Mitesh Rao, founder and CEO of OMNY Health, told MobiHealthNews that he anticipates a shift in conversation from data security to patient safety, which he said is the ultimate goal.  "There will be an increase in partnerships launched across the industry, especially in the life sciences and between payers and providers," Rao said.  In 2024, OMNY Health launched an AI-powered platform for health technology companies to leverage its data on more than 75 million patients. The first two companies to utilize the data were QuantHealth company ArisGlobal.  Quant Health added OMNY's data to its existing AI technology, trained on a dataset of 350 million patients. The companies said that the collaboration will help QuantHealth's pharma partners accelerate drug development via simulated clinical trials and predict clinical trial outcomes, patient responses and drug efficacy.